{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:06:01Z","timestamp":1785769561372,"version":"3.56.0"},"reference-count":213,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010023","name":"Natural Science Research of Jiangsu Higher Education Institutions of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.seminoncol.2026.152522","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:29:22Z","timestamp":1783380562000},"page":"152522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulation of PD-1 and PD-L1 expression in tumor immune microenvironment"],"prefix":"10.1016","volume":"53","author":[{"given":"Peilin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.seminoncol.2026.152522_bib0001","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.immuni.2024.04.026","article-title":"The CD8(+) T cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defects","volume":"57","author":"Van Der Byl","year":"2024","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152522_bib0002","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41577-023-00867-9","article-title":"Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1","volume":"23","author":"Chamoto","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0003","article-title":"The role of PD-1 signaling in health and immune-related diseases","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"issue":"1-3","key":"10.1016\/j.seminoncol.2026.152522_bib0004","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152522_bib0005","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J Exp Med"},{"issue":"7077","key":"10.1016\/j.seminoncol.2026.152522_bib0006","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152522_bib0007","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trend Immunol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152522_bib0008","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152522_bib0010","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1038\/s41418-023-01219-9","article-title":"USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1","volume":"30","author":"Kuang","year":"2023","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0011","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12943-019-1073-4","article-title":"EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression","volume":"18","author":"Peng","year":"2019","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0012","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/s41467-021-22173-5","article-title":"The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation","volume":"12","author":"Shang","year":"2021","journal-title":"Nat Commun"},{"issue":"26","key":"10.1016\/j.seminoncol.2026.152522_bib0013","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0014","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s12967-024-05498-9","article-title":"CircRHBDD1 promotes immune escape via IGF2BP2\/PD-L1 signaling and acts as a nanotherapeutic target in gastric cancer","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0015","article-title":"Clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis","author":"Sun","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0016","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152522_bib0017","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0018","article-title":"The features and management of acquired resistance to PD1-based therap y in metastatic melanoma","volume":"196113441","author":"Hepner","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0019","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-020-1144-6","article-title":"Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy","volume":"19","author":"Ren","year":"2020","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152522_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006464","article-title":"Predictive biomarkers for PD-1\/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data","volume":"11","author":"So","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152522_bib0022","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152522_bib0023","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"5502","key":"10.1016\/j.seminoncol.2026.152522_bib0024","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152522_bib0025","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152522_bib0026","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152522_bib0027","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1084\/jem.193.7.839","article-title":"B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells","volume":"193","author":"Tseng","year":"2001","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152522_bib0028","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"issue":"19","key":"10.1016\/j.seminoncol.2026.152522_bib0029","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"10.1016\/j.seminoncol.2026.152522_bib0030","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152522_bib0031","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/1078-0432.CCR-13-2933","article-title":"Detection of cancer DNA in plasma of patients with early-stage breast cancer","volume":"20","author":"Beaver","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0032","unstructured":"U.S. Food & Drug Administration, Atezolizumab for urothelial carcinoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/atezolizumab-urothelial-carcinoma\/, 2016 (accessed 18 October 2025)."},{"issue":"13","key":"10.1016\/j.seminoncol.2026.152522_bib0033","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.seminoncol.2026.152522_bib0034","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.seminoncol.2026.152522_bib0035","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152522_bib0036","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1078-0432.CCR-16-1069","article-title":"Genomic amplification of CD274 (PD-L1) in small-cell lung cancer","volume":"23","author":"George","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0037","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jtho.2015.09.010","article-title":"PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer","volume":"11","author":"Ikeda","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"7517","key":"10.1016\/j.seminoncol.2026.152522_bib0038","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.seminoncol.2026.152522_bib0039","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"issue":"7607","key":"10.1016\/j.seminoncol.2026.152522_bib0040","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancer s","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152522_bib0041","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152522_bib0042","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41591-021-01388-5","article-title":"Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child","volume":"27","author":"Ogishi","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152522_bib0043","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ng1020","article-title":"A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans","volume":"32","author":"Prokunina","year":"2002","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152522_bib0044","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/cancers13061370","article-title":"Germline variation in PDCD1 is associated with overall survival in patients with metastatic melanoma treated with anti-PD-1 monotherapy","volume":"13","author":"de With","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152522_bib0045","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The epigenomics of cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152522_bib0046","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.immuni.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8+ T cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity"},{"issue":"19","key":"10.1016\/j.seminoncol.2026.152522_bib0047","doi-asserted-by":"crossref","first-page":"8934","DOI":"10.1128\/JVI.00798-16","article-title":"Demethylation of the PD-1 promoter is imprinted during the effector Ph ase of CD8 T cell exhaustion","volume":"90","author":"Ahn","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0048","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03416","article-title":"Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy","volume":"3","author":"McPherson","year":"2014","journal-title":"Elife"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152522_bib0049","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: a rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"\u00d8rskov","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ebiom.2018.01.016","article-title":"PD-1 (PDCD1) promoter methylation is a prognostic factor in patients with diffuse lower-grade gliomas harboring isocitrate dehydrogenase (IDH) mutations","volume":"28","author":"Rover","year":"2018","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0051","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1257454","article-title":"PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients","volume":"6","author":"Goltz","year":"2017","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0052","doi-asserted-by":"crossref","first-page":"641","DOI":"10.18632\/oncotarget.23080","article-title":"PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas","volume":"9","author":"Franzen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0053","article-title":"Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma","author":"Zhu","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152522_bib0054","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0055","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2267744","article-title":"PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma","volume":"12","author":"Klumper","year":"2023","journal-title":"OncoImmunology"},{"issue":"6316","key":"10.1016\/j.seminoncol.2026.152522_bib0056","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvig oration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"issue":"6316","key":"10.1016\/j.seminoncol.2026.152522_bib0057","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152522_bib0058","doi-asserted-by":"crossref","first-page":"djw283","DOI":"10.1093\/jnci\/djw283","article-title":"The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion","volume":"109","author":"Lu","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0059","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s40425-019-0784-9","article-title":"EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma","volume":"7","author":"Xiao","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0060","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13148-022-01316-5","article-title":"Distinct modulation of IFN\u03b3-induced transcription by BET bromodomain a nd catalytic P300\/CBP inhibition in breast cancer","volume":"14","author":"Hogg","year":"2022","journal-title":"Clin Epigenet"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152522_bib0061","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41419-021-04047-2","article-title":"Histone deacetylase 2 knockout suppresses immune escape of triple-nega tive breast cancer cells via downregulating PD-L1 expression","volume":"12","author":"Xu","year":"2021","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152522_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115015","article-title":"Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma","volume":"43","author":"Wang","year":"2024","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152522_bib0063","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1302750","article-title":"STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells","volume":"192","author":"Austin","year":"2014","journal-title":"J Immunol"},{"issue":"7764","key":"10.1016\/j.seminoncol.2026.152522_bib0064","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"issue":"7764","key":"10.1016\/j.seminoncol.2026.152522_bib0065","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"issue":"7764","key":"10.1016\/j.seminoncol.2026.152522_bib0066","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152522_bib0067","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.immuni.2014.10.013","article-title":"The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection","volume":"41","author":"Staron","year":"2014","journal-title":"Immunity"},{"issue":"8010","key":"10.1016\/j.seminoncol.2026.152522_bib0068","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"issue":"8010","key":"10.1016\/j.seminoncol.2026.152522_bib0069","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152522_bib0070","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","article-title":"Akt promotes cell survival by phosphorylating and inhibiting a Forkhea d transcription factor","volume":"96","author":"Brunet","year":"1999","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152522_bib0071","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.immuni.2009.02.003","article-title":"An essential role of the Forkhead-box transcription factor Foxo1 in co ntrol of T cell homeostasis and tolerance","volume":"30","author":"Ouyang","year":"2009","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152522_bib0072","article-title":"CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2\/STAT3 pathway","volume":"4","author":"Cao","year":"2024","journal-title":"Cell Genom"},{"issue":"105","key":"10.1016\/j.seminoncol.2026.152522_bib0073","doi-asserted-by":"crossref","first-page":"eado3032","DOI":"10.1126\/sciimmunol.ado3032","article-title":"Continuous expression of TOX safeguards exhausted CD8 T cell epigeneti c fate","volume":"10","author":"Huang","year":"2025","journal-title":"Sci Immunol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152522_bib0074","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1084\/jem.20130208","article-title":"Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward t ranscriptional circuit during acute viral infection","volume":"211","author":"Lu","year":"2014","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152522_bib0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ni1320","article-title":"Transcriptional repressor Blimp-1 regulates T cell homeostasis and function","volume":"7","author":"Martins","year":"2006","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152522_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114547","article-title":"Chronic viral infection alters PD-1 locus subnuclear localization in c ytotoxic CD8+ T cells","volume":"43","author":"Sacrist\u00e1n","year":"2024","journal-title":"Cell Rep"},{"issue":"14","key":"10.1016\/j.seminoncol.2026.152522_bib0077","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood.2021012714","article-title":"Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic ef ficacy of adoptive immunotherapy","volume":"139","author":"Yoshikawa","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152522_bib0078","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","article-title":"NFATc1 regulates PD-1 expression upon T cell activation","volume":"181","author":"Oestreich","year":"2008","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152522_bib0079","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00018-022-04481-1","article-title":"CD69-oxLDL ligand engagement induces programmed Cell Death 1 (PD-1) ex pression in human CD4\u2009+\u2009T lymphocytes","volume":"79","author":"Jim\u00e9nez-Fern\u00e1ndez","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152522_bib0080","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41419-022-05123-x","article-title":"BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia","volume":"13","author":"Zhong","year":"2022","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152522_bib0081","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","article-title":"The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells","volume":"42","author":"Martinez","year":"2015","journal-title":"Immunity"},{"issue":"38","key":"10.1016\/j.seminoncol.2026.152522_bib0082","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1073\/pnas.1206370109","article-title":"Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1","volume":"109","author":"Xiao","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152522_bib0083","doi-asserted-by":"crossref","first-page":"872","DOI":"10.4049\/immunohorizons.2100112","article-title":"IL-6\/STAT3 signaling axis enhances and prolongs Pdcd1 expression in murine CD8 T cells","volume":"6","author":"Powell","year":"2022","journal-title":"Immunohorizons"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152522_bib0084","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220686","article-title":"STAT3 regulates CD8+ T cell differentiation and functions in cancer and acute infection","volume":"220","author":"Sun","year":"2023","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152522_bib0085","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.ymthe.2024.03.035","article-title":"RNAi mediated silencing of STAT3\/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors","volume":"32","author":"Ganesh","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0086","article-title":"PD-1(+) CD4 T cell immune response is mediated by HIF-1alpha\/NFATc1 pathway after P. yoelii infection","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"issue":"7779","key":"10.1016\/j.seminoncol.2026.152522_bib0087","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152522_bib0088","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00262-018-2186-0","article-title":"Inhibition of the adenosine A2a receptor modulates expression of T cel l coinhibitory receptors and improves effector function for enhanced c heckpoint blockade and ACT in murine cancer models","volume":"67","author":"Leone","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152522_bib0089","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41590-022-01152-y","article-title":"Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells","volume":"23","author":"Sumida","year":"2022","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152522_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111647","article-title":"Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy","volume":"41","author":"Chen","year":"2022","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152522_bib0091","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/2159-8290.CD-15-1347","article-title":"TGFbeta1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer","volume":"6","author":"Park","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110400","article-title":"IFN\u03b3-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling","author":"Padmanabhan","year":"2022","journal-title":"Cell Signal"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0093","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1186\/s12964-024-01963-6","article-title":"Differentiation status determines the effects of IFN\u03b3 on the expressio n of PD-L1 and immunomodulatory genes in melanoma","volume":"22","author":"S\u00e6varsson","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152522_bib0094","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152522_bib0095","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 Expr ession","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152522_bib0096","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/cas.14752","article-title":"Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer","volume":"112","author":"Zhang","year":"2021","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0097","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000285","article-title":"IL-6 promotes PD-L1 expression in monocytes and macrophages by decreas ing protein tyrosine phosphatase receptor type O expression in human h epatocellular carcinoma","volume":"8","author":"Zhang","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152522_bib0098","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010612","article-title":"Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-der ived suppressor cells through IL-6\/Jak\/Stat3 in PD-L1-high lung cancer","volume":"13","author":"Jeong","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152522_bib0099","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ccr.2009.01.023","article-title":"Cancer metastasis is accelerated through immunosuppression during Snai l-induced EMT of cancer cells","volume":"15","author":"Kudo-Saito","year":"2009","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152522_bib0100","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.7150\/thno.69444","article-title":"HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetyla tion in pancreatic cancer","volume":"12","author":"Zhou","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0101","article-title":"Inflammatory cytokines IL-17 and TNF-\u03b1 up-regulate PD-L1 expression in human prostate and colon cancer cells","volume":"1847-14","author":"Wang","year":"2017","journal-title":"Immunol Lett"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152522_bib0102","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1423170","article-title":"PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma","volume":"7","author":"Asgarova","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0103","article-title":"M1 macrophages induce PD-L1 expression in hepatocellular carcinoma Cel ls through IL-1\u03b2 signaling","author":"Zong","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152522_bib0104","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2024.03.009","article-title":"The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152522_bib0105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherap y by suppressing IL-12 expression in intratumoral dendritic cells","volume":"26","author":"Ruffell","year":"2014","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.seminoncol.2026.152522_bib0106","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.3390\/cancers13164011","article-title":"IL-27 mediates PD-L1 expression and release by human mesothelioma cell s","volume":"13","author":"Carbotti","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152522_bib0107","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1038\/s41418-021-00781-4","article-title":"PLK1\/vimentin signaling facilitates immune escape by recruiting Smad2\/3 to PD-L1 promoter in metastatic lung adenocarcinoma","volume":"28","author":"Jang","year":"2021","journal-title":"Cell Death Differ"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152522_bib0108","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152522_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109181","article-title":"PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR","volume":"35","author":"Ghosh","year":"2021","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152522_bib0110","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"issue":"18","key":"10.1016\/j.seminoncol.2026.152522_bib0111","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated wit h low response rates to PD-1 pathway blockade in non\u2013small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0112","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","article-title":"The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy","volume":"13","author":"Yuan","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152522_bib0113","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41419-022-05292-9","article-title":"PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152522_bib0114","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-12-2731","article-title":"The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition","volume":"19","author":"Jiang","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-018-0803-3","article-title":"PTEN\/PTENP1: 'Regulating the regulator of RTK-dependent PI3K\/Akt signalling', new targets for cancer therapy","volume":"17","author":"Haddadi","year":"2018","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152522_bib0116","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/hep.29890","article-title":"PRDM8 exhibits antitumor activities toward hepatocellular carcinoma by targeting NAP1L1","volume":"68","author":"Chen","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152522_bib0117","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152522_bib0118","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ijc.32140","article-title":"Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer","volume":"145","author":"Kim","year":"2019","journal-title":"Int J Cancer"},{"issue":"38","key":"10.1016\/j.seminoncol.2026.152522_bib0119","doi-asserted-by":"crossref","first-page":"63901","DOI":"10.18632\/oncotarget.19194","article-title":"EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release","volume":"8","author":"Suh","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152522_bib0120","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3390\/cells9081830","article-title":"NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer","volume":"9","author":"Huang","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112259","article-title":"Buparlisib modulates PD-L1 expression in head and neck squamous cell c arcinoma cell lines","volume":"396","author":"Fiedler","year":"2020","journal-title":"Exp Cell Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0122","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13046-022-02243-2","article-title":"RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion","volume":"41","author":"Zhang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0123","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5483\/BMBRep.2021.54.1.241","article-title":"Current understanding of cancer-intrinsic PD-L1: regulation of express ion and its protumoral activity","volume":"54","author":"Yadollahi","year":"2021","journal-title":"BMB Rep"},{"issue":"52","key":"10.1016\/j.seminoncol.2026.152522_bib0124","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152522_bib0125","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","article-title":"Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152522_bib0126","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010151","article-title":"Hypoxia upregulates the expression of PD-L1 via NPM1 in breast cancer","volume":"13","author":"Yu","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0127","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40164-023-00378-2","article-title":"Hypoxia-associated circPRDM4 promotes immune escape via HIF-1\u03b1 regulat ion of PD-L1 in hepatocellular carcinoma","volume":"12","author":"Chen","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152522_bib0128","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159473","article-title":"Cross-talk between HIF and PD-1\/PD-L1 pathways in carcinogenesis and therapy","volume":"132","author":"Shurin","year":"2022","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0129","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s12951-023-02203-8","article-title":"TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer","volume":"21","author":"Wang","year":"2023","journal-title":"J Nanobiotechnology"},{"issue":"15","key":"10.1016\/j.seminoncol.2026.152522_bib0130","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2423490122","article-title":"ID3 enhances PD-L1 expression by restructuring MYC to promote colorectal cancer immune evasion","volume":"122","author":"Huang","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0131","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-022-00297-8","article-title":"Current insight into the regulation of PD-L1 in cancer","volume":"11","author":"Liu","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152522_bib0132","first-page":"709","article-title":"Research progress of HGF\/c-met signaling pathway in oral squamous cell carcinoma","volume":"33","author":"Shi","year":"2025","journal-title":"J Prev Treat Stomatol Dis"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0133","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1498391","article-title":"c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity","author":"Jabbarzadeh Kaboli","year":"2024","journal-title":"Front Immunol"},{"issue":"6282","key":"10.1016\/j.seminoncol.2026.152522_bib0134","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152522_bib0135","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152522_bib0136","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","article-title":"BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression","volume":"16","author":"Zhu","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0137","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216726","article-title":"PD-1 regulation in immune homeostasis and immunotherapy","author":"Gao","year":"2024","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152522_bib0138","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cellimm.2005.07.007","article-title":"Alternative splice variants of the human PD-1 gene","volume":"235","author":"Nielsen","year":"2005","journal-title":"Cell Immunol"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152522_bib0139","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0331468","article-title":"Targeting the Exon2 splice cis-element in PD-1 and its effects on lymphocyte function","volume":"20","author":"Tan","year":"2025","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152522_bib0140","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1080\/15476286.2019.1659080","article-title":"Modulation of PDCD1 exon 3 splicing","volume":"16","author":"Sun","year":"2019","journal-title":"RNA Biol"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152522_bib0141","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1158\/2326-6066.CIR-20-0113","article-title":"Tumor cell-derived TGFbeta1 attenuates antitumor immune activity of T cells via regulation of PD-1 mRNA","volume":"8","author":"Wu","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0142","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s42003-023-04922-y","article-title":"Cumulative effects of weakly repressive regulatory regions in the 3\u2019 UTR maintain PD-1 expression homeostasis in mammals","volume":"6","author":"Lai","year":"2023","journal-title":"Commun Biol"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152522_bib0143","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0144","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106507","article-title":"Angiotensin II contributes to intratumoral immunosuppressionvia induct ion of PD-L1 expression in non-small cell lung carcinoma","author":"Yang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0145","first-page":"65686","article-title":"Paeonol inhibits melanoma growth by targeting PD1 through upregulation of miR-139-5p","author":"Chen","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152522_bib0146","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.4049\/jimmunol.2100602","article-title":"Long noncoding RNA lncNDEPD1 regulates PD-1 expression via miR-3619-5p in CD8+ T Cells","volume":"208","author":"Cheng","year":"2022","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152522_bib0147","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3390\/cells10030519","article-title":"MiR-200c-3p contrasts PD-L1 induction by combinatorial therapies and slows proliferation of epithelial ovarian cancer through downregulation of \u03b2-Catenin and c-Myc","volume":"10","author":"Anastasiadou","year":"2021","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152522_bib0148","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3390\/genes14081620","article-title":"The 3\u2032 non-coding sequence negatively regulates PD-L1 expression, and its regulators are systematically identified in pan-cancer","volume":"14","author":"Chen","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0149","article-title":"Aerosolized miR-138-5p and miR-200c targets PD-L1 for lung cancer prevention","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152522_bib0150","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41419-021-04033-8","article-title":"miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1","volume":"12","author":"Chen","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0151","article-title":"Circular RNA CHST15 sponges miR-155-5p and miR-194-5p to promote the immune escape of lung cancer cells mediated by PD-L1","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0152","article-title":"Circular RNA circ_0000284 plays an oncogenic role in the progression of non-small cell lung cancer through the miR-377-3p-mediated PD-L1 promotion","author":"Li","year":"2020","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0153","article-title":"Identification of lncRNA dual targeting PD-L1 and PD-L2 as a novel prognostic predictor for gastric cancer","author":"Zhang","year":"2024","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152522_bib0154","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-21-1323","article-title":"JNK signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6A modification of PD-L1 mRNA","volume":"82","author":"Ni","year":"2022","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.seminoncol.2026.152522_bib0155","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1158\/0008-5472.CAN-21-0468","article-title":"M(6)A demethylase ALKBH5 regulates PD-L1 expression and tumor immunoenvironment in intrahepatic cholangiocarcinoma","volume":"81","author":"Qiu","year":"2021","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152522_bib0156","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/2326-6066.CIR-24-1179","article-title":"METTL3 inhibition restores PD-L1 expression and CD8+ T-cell cytotoxic function in immunotherapy-treated gastric cancer","volume":"13","author":"Fang","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0157","first-page":"24755","article-title":"CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via m(6)A modification in hepatocellular carcinoma","author":"Cai","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0158","article-title":"m(7)G regulator-mediated methylation modification patterns define immune cell infiltration and patient survival","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0159","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12943-025-02397-5","article-title":"Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies","volume":"24","author":"Jia","year":"2025","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0160","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12943-025-02330-w","article-title":"N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1","volume":"24","author":"Kaufman","year":"2025","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0161","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1186\/s12967-024-05502-2","article-title":"N-linked glycosylation of PD-L1\/PD-1: an emerging target for cancer diagnosis and treatment","volume":"22","author":"Duan","year":"2024","journal-title":"J Transl Med"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152522_bib0162","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","article-title":"Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation","volume":"10","author":"Chen","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152522_bib0163","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/s41418-024-01432-0","article-title":"A STT3A-dependent PD-L1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma","volume":"32","author":"Guo","year":"2025","journal-title":"Cell Death Differ"},{"issue":"40","key":"10.1016\/j.seminoncol.2026.152522_bib0164","doi-asserted-by":"crossref","first-page":"68291","DOI":"10.18632\/oncotarget.19309","article-title":"A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma","volume":"8","author":"D'Arrigo","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152522_bib0165","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.celrep.2017.07.027","article-title":"Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells","volume":"20","author":"Okada","year":"2017","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152522_bib0166","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2025.100248","article-title":"Targeting PD-1 post-translational modifications for improving cancer immunotherapy","volume":"4","author":"Shi","year":"2025","journal-title":"Cell Insight"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0167","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12943-024-02046-3","article-title":"Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0168","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1049\/syb2.12086","article-title":"The 'Other' subfamily of HECT E3 ubiquitin ligases evaluate the tumour immune microenvironment and prognosis in patients with hepatocellular carcinoma","volume":"18","author":"Dong","year":"2024","journal-title":"IET Syst Biol"},{"issue":"7670","key":"10.1016\/j.seminoncol.2026.152522_bib0169","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature23643","article-title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","volume":"549","author":"Burr","year":"2017","journal-title":"Nature"},{"issue":"7670","key":"10.1016\/j.seminoncol.2026.152522_bib0170","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature23669","article-title":"Identification of CMTM6 and CMTM4 as PD-L1 protein regulators","volume":"549","author":"Mezzadra","year":"2017","journal-title":"Nature"},{"issue":"7686","key":"10.1016\/j.seminoncol.2026.152522_bib0171","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152522_bib0172","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","article-title":"Deubiquitination and stabilization of PD-L1 by CSN5","volume":"30","author":"Lim","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0173","first-page":"81203","article-title":"The ubiquitin code","author":"Komander","year":"2012","journal-title":"Annu Rev Biochem"},{"issue":"7734","key":"10.1016\/j.seminoncol.2026.152522_bib0174","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-018-0756-0","article-title":"FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells","volume":"564","author":"Meng","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109546","article-title":"Cyclin-dependent kinase 1-mediated phosphorylation of protein kinase N 1 promotes anchorage-independent growth and migration","author":"Zeng","year":"2020","journal-title":"Cell Signal"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152522_bib0176","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005116","article-title":"FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152522_bib0177","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1172\/JCI126022","article-title":"IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion","volume":"129","author":"Chan","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0178","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1186\/s12967-025-06812-9","article-title":"USP5-Mediated PD-L1 deubiquitination regulates immunotherapy efficacy in melanoma","volume":"23","author":"Xie","year":"2025","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152522_bib0179","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","article-title":"Inhibiting PD-L1 palmitoylation enhances T-cell immune responses again st tumours","volume":"3","author":"Yao","year":"2019","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152522_bib0180","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3923\/ijp.2025.259.269","article-title":"PD-L1 palmitoylation by ZDHHC3 contributes to chemoresistance and inhibits CD8+ T cell cytotoxicity in gastric cancer","volume":"21","author":"Li","year":"2025","journal-title":"Int J Pharmacol"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152522_bib0181","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2024.10.019","article-title":"Dual impacts of serine\/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation","volume":"36","author":"Tong","year":"2024","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0182","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41589-018-0161-x","article-title":"HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity","volume":"15","author":"Wang","year":"2019","journal-title":"Nat Chem Biol"},{"issue":"42","key":"10.1016\/j.seminoncol.2026.152522_bib0183","doi-asserted-by":"crossref","first-page":"eadp4917","DOI":"10.1126\/sciadv.adp4917","article-title":"Targeting VPS18 hampers retromer trafficking of PD-L1 and augments immunotherapy","volume":"10","author":"Dong","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0184","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1213375","article-title":"A CD64\/Fc\u03b3RI-mediated mechanism hijacks PD-1 from PD-L1\/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells","author":"Joo","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0185","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1038\/s41467-021-25662-9","article-title":"TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity","volume":"12","author":"Ren","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0186","article-title":"IKZF4\/NONO-RAB11FIP3 axis promotes immune evasion in gastric cancer via facilitating PD-L1 endosome recycling","author":"Weng","year":"2024","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0187","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41420-024-02027-x","article-title":"DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy","volume":"10","author":"Choi","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0188","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217221","article-title":"Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1\/PD-L1 immunotherapy","author":"La Vecchia","year":"2024","journal-title":"Cancer Lett"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152522_bib0189","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12279","article-title":"Suppression of PD-L1 release from small extracellular vesicles promotes systemic anti-tumor immunity by targeting ORAI1 calcium channels","volume":"11","author":"Chen","year":"2022","journal-title":"J Extracell Vesicles"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152522_bib0190","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.celrep.2018.06.066","article-title":"ALIX regulates tumor-mediated immunosuppression by controlling EGFR activity and PD-L1 presentation","volume":"24","author":"Monypenny","year":"2018","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152522_bib0191","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41423-022-00926-6","article-title":"Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1","volume":"19","author":"Chen","year":"2022","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0192","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1038\/s41467-024-48200-9","article-title":"PD-1\/CD80(+) small extracellular vesicles from immunocytes induce cold tumours featured with enhanced adaptive immunosuppression","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0193","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41392-021-00784-0","article-title":"GOLM1 exacerbates CD8(+) T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0194","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217001","article-title":"Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: a retrospective cohort study","author":"Fletcher","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0195","article-title":"Anlotinib enhanced CD8(+) T cell infiltration via induction of CCL5 improves the efficacy of PD-1\/PD-L1 blockade therapy in lung cancer","author":"Luo","year":"2024","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152522_bib0196","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0197","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2024.101027","article-title":"LBA3 perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) in early-stage non-small-cell lung cancer (NSCLC): A 4-year update of KEYNOTE-671","author":"Majem","year":"2024","journal-title":"Immunooncol Technol"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0198","doi-asserted-by":"crossref","first-page":"S1239","DOI":"10.1016\/j.annonc.2024.08.2291","article-title":"LBA50 perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study","volume":"35","author":"Provencio Pulla","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0199","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0200","doi-asserted-by":"crossref","first-page":"S1135","DOI":"10.1016\/j.annonc.2024.08.2049","article-title":"1964MO Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution","volume":"35","author":"Apolo","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0201","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115709","article-title":"Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: the phase 1 study 3475A-C18","author":"Cohen","year":"2025","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152522_bib0202","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","article-title":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.seminoncol.2026.152522_bib0203","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1200\/JCO.24.01124","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from relativity-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0204","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115547","article-title":"Nivolumab plus relatlimab in advanced melanoma: relativity-047 4-year update","author":"Lipson","year":"2025","journal-title":"Eur J Cancer"},{"issue":"10427","key":"10.1016\/j.seminoncol.2026.152522_bib0205","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"16_suppl","key":"10.1016\/j.seminoncol.2026.152522_bib0206","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1200\/JCO.2025.43.16_suppl.8509","article-title":"First-in-class PD-1\/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC)","volume":"43","author":"Zhou","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.seminoncol.2026.152522_bib0207","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1200\/JCO.2025.43.16_suppl.8543","article-title":"A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bi specific antibody targeting PD-1 and VEGF, as a monotherapy in patient s with advanced NSCLC","volume":"43","author":"Wu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.seminoncol.2026.152522_bib0208","doi-asserted-by":"crossref","first-page":"9591","DOI":"10.1200\/JCO.2025.43.16_suppl.9591","article-title":"PD-1\u2013directed intratumoral immunotherapy for cutaneous carcinomas: interim results from an ongoing study of INTASYL PH-762","volume":"43","author":"Spellman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.seminoncol.2026.152522_bib0209","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1200\/JCO.2025.43.4_suppl.553","article-title":"Comparison of efficacy and safety of PD-1 and PD-L1 antibodies in combination with hepatic arterial infusion chemotherapy and target therapy for unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective study","volume":"43","author":"Xiong","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152522_bib0210","article-title":"PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152522_bib0211","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12967-025-06186-y","article-title":"Spatial interaction mapping of PD-1\/PD-L1 in head and neck cancer reveals the role of macrophage-tumour barriers associated with immunotherapy response","volume":"23","author":"Naei","year":"2025","journal-title":"J Transl Med"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152522_bib0212","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/2326-6066.CIR-24-0071","article-title":"Spatially resolved whole-transcriptomic and proteomic profiling of lung cancer and its immune microenvironment according to PD-L1 expression","volume":"12","author":"Koh","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.seminoncol.2026.152522_bib0213","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102442","article-title":"Spatial heterogeneity of PD-L1 expression influence its assessment in esophageal squamous cell carcinoma","volume":"59","author":"Yu","year":"2025","journal-title":"Transl Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:14:39Z","timestamp":1785766479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775426000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":213,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0093775426000692"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152522","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulation of PD-1 and PD-L1 expression in tumor immune microenvironment","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152522"}}